Tenax Therapeutics Reports Subgroup Benefit Despite Phase 3 Trial Missing Primary Endpoint
Tenax Therapeutics (TENX) reported that additional analyses from its failed LEVEL Phase 3 trial suggest potential benefits for a subgroup of pulmonary hypertension patients with more limited exercise capacity. While the primary endpoint was not met in the overall population, these findings may offer some value to investors and stakeholders. The drug under evaluation is an oral formulation of levosimendan, which Tenax believes could still have therapeutic relevance despite the trial's shortcomings. The company will likely need further data or trials to validate this subgroup benefit before moving forward with regulatory submissions or commercialization plans.
Tickers: $TENX